Symptoms of anxiety/depression is associated with more aggressive inflammatory bowel disease

Xin Gao, Yu Tang, Na Lei, Ying Luo, Pingrun Chen, Chang Liang, Shihao Duan & Yan Zhang

Studies have demonstrated that inflammatory bowel disease (IBD) patients are at an increased risk of developing anxiety and/or depression. IBD patients with depression/anxiety have higher rates of hospitalization and increased disease severity than those without. So far, there is a paucity of data concerning the impact of anxiety/depression on Chinese IBD patients. The aim of this study was to find out the prevalence of symptoms of anxiety/depression in Chinese IBD population and its impact on IBD-related features. This is a cross-sectional study from the southwest China IBD referral center. Eligible participants were divided into those with symptoms of anxiety/depression and those without based on the Hospital Anxiety and Depression Scale (HADS). Demographic data and disease duration, IBD-related surgery, tobacco use, extra-intestinal manifestations, disease activity scores, endoscopic evaluation, laboratory data and current medication use were compared between two groups. A total of 341 IBD patients [221 Crohn's disease (CD) and 120 ulcerative colitis (UC)] were included. The prevalence of symptoms of anxiety/depression in IBD was 33.1%. CD patients with symptoms of anxiety/depression tended to have higher scores of simple endoscopic scores for Crohn's disease (SES-CD) (p = 0.0005). UC patients with symptoms of anxiety/depression had a significantly higher Mayo score (p = 0.0017) and ulcerative colitis endoscopic index of severity (UCEIS) (p < 0.0001) than their non-anxiety/depression counterparts. CD-related surgery (p = 0.012) and Crohn's disease activity index (CDAI) (p < 0.0001) were identified as independent risk factors for symptoms of anxiety/depression in CD, while corticosteroid use (p = 0.036) as an independent risk factor for symptoms of anxiety/depression in UC. This study helps our understanding of the prevalence of symptoms of anxiety/depression in IBD patients and its impact on IBD course and reminds us to pay more attention on IBD management with anxiety/depression.

In 1970s, CD patients were first found to be significantly more anxious, neurotic and introverted than both the test norms and the non-psychosomatic medical out-patients and did not differ appreciably from the psychosomatic patients in these respects1. Since then, several studies have demonstrated that IBD was associated with psychiatric disorders. The prevalence of anxiety and depression in IBD was at least twice that of the general population2,3. Up to 34.7% of IBD patients in active stage were found to have comorbid depression compared with 19.9% of inactive IBD patients4. IBD patients with anxiety and depression are therapeutically more demanding and consuming more healthcare resources4. Patients with history of depression were more likely to develop IBD, which could be selectively protected by certain antidepressant treatments5.

However, the above observations and findings were mainly based on IBD populations from western countries. With the urbanization and westernization, the incidence and prevalence of IBD are increasing in China6–8. A systematic review and meta-analysis showed that the summary incidence rate of IBD in China was 1.74 per 100,000 person years, and the corresponding incidence rates of CD and UC were 0.4 and 1.18 per 100,000 person years, respectively6. Meanwhile, a recent national survey revealed that the prevalence of psychiatric diseases in the Chinese population is on the rise, with the life time prevalence rates of anxiety and depressive disorders up to 7.6% and 6.8% respectively7. IBD and mental health concerns impose huge burden on their sufferers physically, mentally, and financially8,9. To our knowledge, few studies have focused on the comorbidity of anxiety/depression in Chinese IBD patients. Thus, the present study aimed to determine the prevalence of symptoms of anxiety/depression in Chinese IBD population and comprehensively analyze the impact of symptoms of anxiety/depression on IBD-related features.

Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, People’s Republic of China.

*email: hxzyan@163.com
Methods

Study population. This is a cross-sectional study. Patients with established diagnosis of CD or UC between September 2017 and December 2019 in West China Hospital of Sichuan University, the largest IBD center in the southwest China were included. The inclusion criteria included: (1) meet the standard criteria for CD or UC, which is based on a combination of clinical, biochemical, stool, endoscopic, cross-sectional imaging, and histological investigations; (2) hospitalized IBD patients, who were willing to participate in our study and could complete the questionnaires. The indication for hospitalization included surgery, disease flare or treatment adjustment. Patients met any one of the following criteria were excluded: (1) concomitant with other psychiatric diseases (other than depression or anxiety disorders) or dementia; (2) some severe chronic diseases, like chronic heart failure and chronic obstructive pulmonary disease, other immune disorders and cancer, which may also cause depression; (3) pregnancy;(4) individuals without full capacity of civil conduct. If a patient may require hospitalization more than once, this patient was only included in the study once.

The diagnosis of CD and UC was based on the third European Evidence-based Consensus on Diagnosis and Management of Crohn's disease and Ulcerative Colitis1,12. Anxiety and depression symptoms were determined using the Hospital Anxiety and Depression Scale (HADS) questionnaire. Patients completed the questionnaire at the time of the first clinical encounter recorded within this study period with the help of doctors, and a subscore ≥ 8 indites of anxious or depressive state. Participants were divided into two groups, IBD patients with symptoms of anxiety/depression and without. Other questionnaires, including the Inflammatory Bowel Disease Questionnaire (IBDQ), the Composite Autonomic Symptom Score (COMPASS)-31, the Fatigue Severity Scale (FSS) and the Pittsburgh Sleep Quality Index (PSQI) were also asked to be completed at the same time. IBDQ is a disease-specific tool to assess the disease consequences on patient’s quality of life13. The COMPASS-31 is a concise and statistically robust instrument to assess autonomic symptoms that provides clinically relevant scores of autonomic symptom severity14. FSS and PSQI were used to evaluate the patients' fatigue and quality of sleep15,16.

Patient demographics, disease duration, IBD-related surgery, tobacco use, extra-intestinal manifestations, disease activity scores [Crohn’s disease activity index (CDAI) for CD and Mayo score for UC], endoscopic evaluation [Simple Endoscopic Score for Crohn’s disease (SES-CD) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS)], laboratory data [white blood count (WBC), albumin (ALB), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)] and current medication use were recorded and compared between the IBD patients with symptoms of anxiety/depression and without. IBD-related surgery was defined as patients underwent surgery because of IBD associated stricture, fistula, perforation or cancer at this or previous admissions.

Statistical analysis. Data was extracted and analyzed with SPSS 22.0 and GraphPad Prism 7.0 software. Continuous variables were presented as median values [interquartile range (IQR)], while categorical variables were presented as percentages. Mann–Whitney U test was used to compare two groups which were continuous variables, and the Pearson chi-square test for categorical variables. Multivariable logistic regression with predictors of symptoms of anxiety and depression in IBD patients were analyzed. Covariates were determined if they reached a threshold level of significance in univariate analyses. Statistically significance was considered achieved for p < 0.05. Of note, we also performed analysis of IBD subtypes.

Statement of ethics. This study was approved by the Ethics Committee of West China Hospital of Sichuan University and carried out in accordance with the Helsinki Declaration. The purpose and methods of the study were explained to all participants. Written informed consent was obtained from each participant prior to enrollment.

Results

Clinical features of IBD patients with symptoms of anxiety/depression. One hundred and thirteen of 341 IBD patients (33.1%) including 120 UC and 221 CD were found to have symptoms of anxiety/depression (Table 1). Prevalence of anxiety/depression was similar between UC and CD (36.7% vs 31.2% respectively; p = 0.336). IBD patients with symptoms of anxiety/depression were older (p = 0.0003), and had lower levels of ALB [35.3 (29.6, 39.7) vs 37.5 (33.1, 42.2), p = 0.0017] compared to those without. Higher level of ESR [49 (31, 71) vs 38 (22, 66), p = 0.0162] and higher frequency of corticosteroid use (44.2% vs 27.6%, p = 0.0032) were observed in patients with symptoms of anxiety/depression. Patients with symptoms of anxiety/depression were more likely to undergo IBD-related surgery (43.4% vs 29.4%, p = 0.0149). Besides, patients with symptoms of anxiety/depression had significantly lower quality of life [125 (97, 140) vs 180 (154, 199), p < 0.0001], which is measured by IBDQ. Increased severity of autonomic symptoms were observed in IBD patients with symptoms of anxiety/depression [26 (15, 39) vs 13 (8, 26), p < 0.0001]. Moreover, those patients tended to have higher scores of FSS and PSQI [48 (38, 57) vs 37 (24, 47), 12 (8, 15) vs 6 (4, 9), p < 0.0001, respectively], which meant they were more likely to suffer from poor sleep and more prone to fatigue. (Table 1).

Symptoms of anxiety/depression aggravated the severity of IBD. No significant differences were found in age, gender, disease duration, tobacco use between CD patients with symptoms of anxiety/depression and those without (p = 0.1260, 0.0698, 0.8304, 0.7377, respectively). Based on Montreal classification, the disease age, location and behavior were similar between the two CD groups (Table 2). CD patients with symptoms of anxiety/depression tended to have higher CDAI (p < 0.0001), and higher SES-CD (p = 0.0005). White blood cell count or albumin level were not significantly different between the two groups (p = 0.2346, 0.0662, respectively), while inflammatory markers including CRP (p = 0.0190) and ESR (p = 0.0245) were higher in CD patients with symptoms of anxiety/depression versus those without. Furthermore, CD patients with symptoms of anxiety/
depression were also more frequently prescribed corticosteroid (42.0% vs 28.3%, \( p = 0.0434 \)) and were more likely to undergo CD-related surgery (56.5% vs 41.5%, \( p = 0.0372 \)) (Table 2).

UC patients with symptoms of anxiety/depression were in older age \([50 (33, 55) \text{ vs } 35 (27, 50), p = 0.0037]\). No difference in gender \( (p = 0.0587) \), disease duration \( (p = 0.8354) \), tobacco use \( (p = 0.5891) \), disease activity \( (p = 0.5095) \), disease distribution \( (p = 0.6591) \) and extra-intestinal manifestations \( (p > 0.9999) \) was revealed between the two UC groups. UC with symptoms of anxiety/depression had significantly higher Mayo scores \([10 (8.5, 11) \text{ vs } 8 (7, 9), p = 0.0017]\), higher UCEIS \([6 (4.75, 7) \text{ vs } 4 (3, 5), p < 0.0001]\), lower albumin levels \([34.0 (28.2, 41.7) \text{ vs } 40.1 (32.5, 44.0), p = 0.0070]\) and were more likely to undergo UC-related surgery (22.7% vs 5.3%, \( p = 0.0067 \)). Besides, corticosteroid was also more frequently prescribed (47.7% vs 26.3%, \( p = 0.0273 \)) for UC patients with symptoms of anxiety/depression. Inflammatory markers such as WBC \( (p = 0.9177) \), CRP \( (p = 0.7314) \) and ESR \( (p = 0.1377) \) were comparable between two groups (Table 3).

### Different markers predicted symptoms of anxiety/depression in IBD patients.

As shown by multivariable logistic regression, CD-related surgery and CDAI were independently associated with symptoms of anxiety/depression in CD patients, while corticosteroid use was a predictor of symptoms of anxiety/depression in UC patients. (Tables 4 and 5).

### Discussion

IBD is a relapsing and disabling disease, and its prevalence is increasing worldwide\(^{17-20}\). Disease-related stress, financial burden, and some other unrecognized factors may lead to the significantly higher prevalence of symptoms of anxiety/depression in IBD patients compared with that of the general population\(^{19-25}\). A cohort study found that 40.1% IBD participants met the criteria for diagnosis of depression and 30.6% met criteria for anxiety. However, one-third of participants with depression and two-thirds with anxiety were undiagnosed, especially males\(^{26}\). The effects of an untreated mental illness can be devastating and can worsen the disease course of IBD\(^{27}\). So, it’s important to timely recognize the mental disorders in the IBD population. To the best of our knowledge, the present study unveiled the state of suffering from symptoms of anxiety/depression in the Chinese IBD population with the largest sample size so far.

Some studies have reported discrepancies as to the prevalence of anxiety and depression and their impact upon IBD subtypes. In a prospective cohort study, depression was associated with an increased risk of CD, but

### Table 1. Characteristics of the entire cohort. CD Crohn's disease, UC ulcerative colitis, IBD inflammatory bowel disease, WBC white blood count, ALB albumin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TNF tumor necrosis factor, IBDQ inflammatory bowel disease questionnaire, COMPASS composite autonomic symptom score, FSS fatigue severity scale, PSQI Pittsburgh sleep quality index, IQR interquartile range.
Our study demonstrated no significant difference of prevalence of symptoms of A&D between UC and CD. However, it is revealed that the age-adjusted hospitalization rate for CD was 26.9/100,000 and 13.3 per 100,000 for UC, which may explain that CD patients required hospitalization far outnumbered UC patients in our study.

With deep cognition about IBD, quality of life and their mental status are also receiving wide attention. A French cohort showed that a half of IBD patients have reported poor quality of life, severe fatigue. Another review showed that fatigue was reportedly prevalent in 41–48% of patients with IBD in remission and 86% of those in active stage. CD patients with impaired sleep had a twofold increase in risk of active disease at 6 months. However, most of these studies were based on populations from western countries, and the relationship between the above factors were also obscure. The present study was representative of the Chinese IBD population since it was conducted in the largest IBD center of southwest China. In our study, IBD patients with symptoms of anxiety/depression were predisposed to have decreased quality of life and sleep compared with their non-anxiety/depression counterparts. Dysfunction of autonomic nerve and fatigue were more common in participants with symptoms of anxiety/depression. Moreover, we also found that patients with symptoms of anxiety/depression were older, and had lower levels of ALB, which disaccorded to Navabi’s study on USA IBD patients.

We identified history of surgery and CDAI as independent predictors of symptoms of anxiety/depression in Chinese CD patients. In contrast, Navabi et al. demonstrated immunomodulator use, history of extra-intestinal manifestations and history of tobacco use as predictors of anxiety/depression in CD, which was inconsistent with our findings. Another study found that anxiety was significantly correlated with female sex, history of perianal disease and perianal surgery in CD patients, which was partly in agreement with our results. These discrepancies may be attributed either to the heterogeneity of participants including races, regions, social cultures, economic

| Variable                               | Without symptoms of anxiety/depression (n = 152) | With symptoms of anxiety/depression (n = 49) | p value |
|----------------------------------------|--------------------------------------------------|---------------------------------------------|---------|
| Age (years) median (IQR)              | 31 (23, 40)                                      | 34 (24, 42)                                 | 0.1260  |
| Women (%)                             | 45 (29.6)                                        | 29 (42.0)                                   | 0.0698  |
| Disease duration (months), median (IQR)| 36 (12, 72)                                      | 36 (12, 78)                                 | 0.8304  |
| Tobacco use, n (%)                    |                                                  |                                             |         |
| Never                                 | 116 (76.3)                                       | 55 (79.7)                                   | 0.7377  |
| Quitted                               | 16 (10.5)                                        | 5 (7.2)                                     |         |
| Current                               | 20 (13.2)                                        | 9 (13.0)                                    |         |
| Montreal age, n (%)                   |                                                  |                                             |         |
| A1 (< 17 years)                       | 9 (5.9)                                          | 3 (4.3)                                     | 0.1965  |
| A2 (17–40 years)                      | 117 (77.0)                                       | 47 (68.1)                                   |         |
| A3 (> 40 years)                       | 26 (17.1)                                        | 19 (27.5)                                   |         |
| Montreal location, n (%)              |                                                  |                                             |         |
| L1                                    | 44 (28.9)                                        | 14 (20.3)                                   | 0.1780  |
| L2                                    | 22 (14.5)                                        | 16 (23.2)                                   |         |
| L3                                    | 86 (56.6)                                        | 39 (56.5)                                   |         |
| Montreal behavior, n (%)              |                                                  |                                             |         |
| B1                                    | 75 (49.3)                                        | 34 (49.3)                                   | 0.6513  |
| B2                                    | 51 (33.6)                                        | 20 (29.0)                                   |         |
| B3                                    | 26 (17.1)                                        | 15 (21.7)                                   |         |
| Extra-intestinal manifestations, n (%)| 18 (11.8)                                        | 12 (17.4)                                   | 0.2644  |
| Surgeries, n (%)                      | 63 (41.5)                                        | 39 (56.5)                                   | 0.0372  |
| CDAI, median (IQR)                    | 189.5 (144.0, 280.0)                             | 356.0 (288.5, 436.0)                        | <0.0001 |
| SES-CID, median (IQR)                 | 12 (8, 15)                                       | 13 (11, 18)                                 | 0.0005  |
| WBC (× 10⁹/L), median (IQR)           | 6.49 (4.76, 8.56)                                | 6.05 (4.75, 7.79)                           | 0.2346  |
| ALB (g/L), median (IQR)               | 37.1 (33.2, 41.3)                                | 35.4 (31.2, 39.5)                           | 0.0662  |
| CRP (mg/L), median (IQR)              | 19.6 (6.9, 54.5)                                 | 39.8 (10.7, 76.5)                           | 0.0190  |
| ESR (mm/h), median (IQR)              | 42.5 (24.0, 69.8)                                | 51.0 (37.5, 73.5)                           | 0.0245  |
| Mesalazine, n (%)                     | 45 (29.6)                                        | 20 (29.0)                                   | 0.9253  |
| Corticosteroid, n (%)                 | 43 (28.3)                                        | 29 (42.0)                                   | 0.0434  |
| Immunomodulator, n (%)                | 83 (54.6)                                        | 44 (63.8)                                   | 0.2017  |
| Anti-TNF, n (%)                       | 43 (28.3)                                        | 19 (27.4)                                   | 0.9080  |

Table 2. Characteristics of the CD cohort. CD Crohn’s disease, CDAI Crohn’s disease activity index, SES-CID Simple Endoscopic Score for Crohn’s disease, WBC white blood count, ALB albumin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TNF tumor necrosis factor, IQR interquartile range.
conditions, or to the methodology of studies such as standards and protocols. In addition, endoscopic score was found to be the independent risk factors for the symptoms of anxiety/depression. Further studies are needed to define the role of endoscopic score in predicting anxiety/depression for CD.

When it comes to UC patients, corticosteroid use was found to be a predictor of symptoms of anxiety/depression in our study. This is also inconsistent with Navabi’s study which revealed that disease duration and immunomodulator use to be predictors of anxiety/depression in UC. Previous research found that initial medical management of IBD was different among countries. For instance, UC patients were more likely to receive immunomodulators in the United States. In contrast, moderate-to-severe UC patients in China were often given corticosteroid as the first-line therapy. The fact that most of our participants were moderate-to-severe UC patients may explain that corticosteroid rather than immunomodulator use was an independent predictor. In addition, colectomy is used as the rescue therapy which brings better quality of life for UC, but might be a

### Table 3. Characteristics of the UC cohort. UC ulcerative colitis, UCEIS ulcerative colitis endoscopic index of severity, WBC white blood count, ALB albumin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TNF tumor necrosis factor, IQR interquartile range.

| Variable                          | Without symptoms of anxiety/depression (n = 69) | With symptoms of anxiety/depression (n = 44) | p value |
|-----------------------------------|-----------------------------------------------|---------------------------------------------|---------|
| Age (years) median (IQR)          | 35 (27, 50)                                   | 50 (33, 55)                                 | 0.0037  |
| Women (%)                         | 40 (52.6)                                     | 15 (34.1)                                   | 0.0587  |
| Disease duration (months) median (IQR) | 29 (20, 90)                                   | 36 (7.5, 84)                                | 0.8354  |
| **Tobacco use, n**                |                                               |                                             |         |
| Never                             | 55 (72.4)                                     | 28 (63.6)                                   | 0.5891  |
| Quitted                           | 15 (19.7)                                     | 12 (27.3)                                   |         |
| Current                           | 6 (7.9)                                       | 4 (9.1)                                     |         |
| **Disease activity, n (%)**       |                                               |                                             | 0.5095  |
| Remission                         | 8 (10.5)                                      | 2 (4.5)                                     |         |
| Mild                              | 10 (13.2)                                     | 4 (9.1)                                     |         |
| Moderate                          | 12 (15.8)                                     | 6 (13.6)                                    |         |
| Severe                            | 46 (60.5)                                     | 32 (72.7)                                   |         |
| **Disease distribution, n (%)**   |                                               |                                             |         |
| E1                                | 8 (10.5)                                      | 3 (6.8)                                     | 0.6591  |
| E2                                | 22 (29.0)                                     | 11 (25.0)                                   |         |
| E3                                | 46 (60.5)                                     | 30 (68.2)                                   |         |
| Extra-intestinal manifestations, n (%) | 8 (10.5)                                    | 4 (9.1)                                     | > 0.9999|
| Surgeries, n (%)                  | 4 (5.3)                                       | 10 (22.7)                                   | 0.0067  |
| Mayo score, median (IQR)          | 8 (7, 9)                                      | 10 (8.5, 11)                                | 0.0017  |
| UCEIS, median (IQR)               | 4 (3, 5)                                      | 6 (4.75, 7)                                 | < 0.0001|
| WBC (× 10^9/L), median (IQR)      | 7.21 (5.03, 8.90)                             | 6.90 (5.78, 9.16)                           | 0.9177  |
| ALB(g/L), median (IQR)            | 40.1 (32.5, 44.0)                             | 34.0 (28.2, 41.7)                           | 0.0070  |
| CRP (mg/L), median (IQR)          | 11.4 (3.1, 38.2)                              | 16.7 (7.2, 43.0)                            | 0.7314  |
| ESR (mm/h), median (IQR)          | 27 (16, 47)                                   | 41 (24, 66)                                 | 0.1377  |
| Mesalazine, n (%)                 | 48 (63.2)                                     | 21 (47.7)                                   | 0.1259  |
| Corticosteroid, n (%)             | 20 (26.3)                                     | 21 (47.7)                                   | 0.0273  |
| Immunomodulator, n (%)            | 10 (13.2)                                     | 6 (13.6)                                    | > 0.9999|
| Anti-TNF, n (%)                   | 6 (7.9)                                       | 4 (9.1)                                     | > 0.9999|

### Table 4. Predictors of symptoms of anxiety and depression in CD patients. CD Crohn’s disease, CDAI Crohn’s disease activity index, SES-CD Simple Endoscopic Score for Crohn’s disease, CRP C-reactive protein, OR odds ratio.

| Variable                          | p value   | OR       | 95% confidence interval |
|-----------------------------------|-----------|----------|-------------------------|
| No history of surgery             | 0.012     | 0.385    | 0.183 0.810             |
| CDAI                              | < 0.0001  | 1.011    | 1.007 1.014             |
| SES-CD                            | 0.078     | 1.079    | 0.992 1.173             |
| CRP                               | 0.464     | 1.003    | 0.994 1.013             |
| ESR                               | 0.477     | 1.005    | 0.991 1.019             |
| Corticosteroid use                | 0.162     | 1.730    | 0.802 3.732             |
fuse for severe complications in CD, such as fistula, stricture and short bowel syndrome. This may also explain that the surgery being an independent predictor for symptoms of anxiety/depression in CD rather than in UC.

There are limitations in the present study. Firstly, participants were limited to hospitalized patients, who had worsened disease course compared with outpatients. A study encompassing IBD outpatients showed that the prevalence of depression was 25%, which could not be neglected in the management of IBD. Secondly, this is a cross-sectional, single-center study, despite the largest IBD referral center of the southwest China. Therefore, longitudinal multi-center studies are needed in the future to further strengthen our findings.

In conclusion, this study delineated the impact of symptoms of anxiety/depression on Chinese IBD population and necessitated special attention paid on mental disorders in IBD patients by physicians. Moreover, timely recognition and even psychiatric treatment are very important to improve the prognosis of IBD.

Received: 10 September 2020; Accepted: 4 January 2021
Published online: 14 January 2021

### References

1. Sheffield, B. F. & Carney, M. W. Crohn's disease: A psychosomatic illness?. *Br. J. Psychiatry* 128, 446–450 (1976).
2. Mikocka-Walus, A. *et al.* Controversies revisited. *Inflamm. Bowel Dis.* 22(3), 752–762 (2016).
3. Mikocka-Walus, A. & Andrews, J. M. It is high time to examine the psyche while treating IBD. *Nat. Rev. Gastroenterol. Hepatol.* 15(6), 329–330 (2018).
4. Navabi, S. *et al.* Influences and impact of anxiety and depression in the setting of inflammatory bowel disease. *Inflamm. Bowel Dis.* 24(11), 2303–2308 (2018).
5. Frolkis, A. D. *et al.* Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. *Gut* 68(9), 1606–1612 (2019).
6. Wang, F. & Ouyang, Q. Ulcerative colitis in China: Retrospective analysis of 3100 hospitalized patients. *J. Gastroenterol. Hepatol.* 32(2), 1430–1435 (2007).
7. APDW Chinese IBD Working Group. Retrospective analysis of 515 cases of Crohn’s disease hospitalization in China: Nationwide study from 1990 to 2003. *J. Gastroenterol. Hepatol.* 21(6), 1009–1015 (2006).
8. Li, X. *et al.* The disease burden and clinical characteristics of inflammatory bowel disease in the Chinese population: A systematic review and meta-analysis. *Int. J. Environ. Res. Public Health* 14(3), 238 (2017).
9. Huang, Y. *et al.* Prevalence of mental disorders in China: A cross-sectional epidemiological study. *Lancet Psychiatry* 6(3), 211–224 (2019).
10. Panara, A. J. *et al.* The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: A cohort study. *Aliment Pharmacol. Ther.* 39(8), 802–810 (2014).
11. Gomollón, F. *et al.* 3rd European Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and Medical Management. *J. Crohns Colitis* 11(1), 3–25 (2016).
12. Magro, F. *et al.* Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *J. Crohns Colitis* 11(6), 649–670 (2017).
13. Chen, X. *et al.* Inflammatory bowel disease-specific health-related quality of life instruments: A systematic review of measurement properties. *Health Qual. Life Outcomes* 15(1), 1 (2017).
14. Sletten, D. M. *et al.* COMPASS 31: A refined and abbreviated composite autonomic symptom score. *Mayo Clin. Proc.* 87(12), 1196–1201 (2012).
15. Hewlett, S., Dures, E. & Almeida, C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS30R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACT-T), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MDFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). *Arthritis Care Res. (Hoboken)* 63(Suppl 11), S263–S286 (2011).
16. Del, R. J. *et al.* Validation of the Portuguese version of the Pittsburgh Sleep Quality Index (PSQI-PT). *Psychiatry Res.* 247, 225–229 (2017).
17. Bernstein, C. N. *et al.* Increased burden of psychiatric disorders in inflammatory bowel disease. *Inflamm. Bowel Dis.* 25(2), 360–368 (2019).
18. Cosnes, J. *et al.* Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 140(6), 1785–1794 (2011).
19. Ananthakrishnan, A. N. *et al.* Association between depressive symptoms and incidence of Crohn’s disease and ulcerative colitis: Results from the Nurses’ Health Study. *Clin. Gastroenterol. Hepatol.* 11(1), 57–62 (2013).
20. Nicolas Williet, H. S. C. G. Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients. *J. Crohns Colitis* 11, 165–174 (2017).
21. van Langenberg, D. R. & Gibson, P. R. Systematic review: Fatigue in inflammatory bowel disease. *Aliment. Pharmacol. Ther.* 32(2), 131–143 (2010).

### Table 5. Predictors of symptoms of anxiety and depression in UC patients. UC ulcerative colitis. UCEIS ulcerative colitis endoscopic index of severity. OR odds ratio.

| Variable                  | p value | OR  | 95% confidence interval |
|---------------------------|---------|-----|-------------------------|
| Age                       | 0.187   | 0.899 | 0.767–1.053 |
| No history of surgery     | 0.462   | 1.765 | 0.389–8.017 |
| Mayo score                | 0.706   | 0.851 | 0.369–1.966 |
| Albumin level             | 0.878   | 0.950 | 0.494–1.828 |
| UCEIS                     | 0.421   | 2.253 | 0.312–16.292 |
| Corticosteroid use        | 0.036   | 3.041 | 1.076–8.593 |
22. Ananthakrishnan, A. N. et al. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. *Clin. Gastroenterol. Hepatol.* 11(8), 965–971 (2013).
23. Engel, T., Ben-Horin, S. & Beer-Gabel, M. Autonomic dysfunction correlates with clinical and inflammatory activity in patients with Crohn’s disease. *Inflamm. Bowel Dis.* 21(10), 2320–2326 (2015).
24. Pellissier, S. et al. Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome. *Psychoneuroendocrinology* 35(5), 653–662 (2010).
25. Bernstein, C. N. & Nabalamba, A. Hospitalization, surgery, and readmission rates of IBD in Canada: A population-based study. *Am. J. Gastroenterol.* 101(1), 110–118 (2006).
26. Lewis, K. et al. The prevalence and risk factors of undiagnosed depression and anxiety disorders among patients with inflammatory bowel disease. *Inflamm. Bowel Dis.* 25(10), 1674–1680 (2019).
27. Kiebles, J. L., Doerfler, B. & Keefer, L. Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. *Inflamm. Bowel Dis.* 16(10), 1685–1695 (2010).
28. Maconi, G. et al. Perianal disease is associated with psychiatric co-morbidity in Crohn's disease in remission. *Int. J. Colorectal Dis.* 29(10), 1285–1290 (2014).
29. Varma, S. et al. Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China. *JGH Open* 3(3), 234–241 (2019).
30. Wu Kaichun, L. J. R. Z. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018). *Chin. J. Dig.* 38(5), 292–311 (2018).
31. Antoni, M. et al. Analysis of risk factors and postoperative complications in patients with Crohn's disease. *Arch. Gastroenterol.* 55(3), 252–257 (2018).
32. Zhang, C. K. et al. The influence of depression on quality of life in patients with inflammatory bowel disease. *Inflamm. Bowel Dis.* 19(8), 1732–1739 (2013).

**Author contributions**
X.G. and Y.T. wrote the main manuscript text and N.L. and Y.L. collected data, C.L., P.C. and S.D. prepared tables. Y.Z. edited the article. All authors reviewed the manuscript.

**Funding**
This work was supported by Grants from National Natural Science Fund of China (81770550).

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to Y.Z.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021